Cempra Pharmaceuticals Inc CEO and leadership

Dr. Prabhavathi Fernandes has been President and Chief Executive Officer of Cempra Pharmaceuticals since its inception in January 2006. She was previously President and Chief Executive Officer of DarPharma, Ricerca Biosciences and Small Molecule Therapeutics. Prior to this, Dr. Fernandes held leadership positions at pharmaceutical corporations having worked at Bristol-Myers Squibb, Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. During these years she was directly involved in the development of antibiotics, four of which have been approved and one, Clarithromycin, achieving sales over a billion dollars. Dr. Fernandes has served on the U.S. Congressional Panel for Assessment of Impact of Antibiotic Resistant Bacteria and on the American Society for Microbiology Advisory Panel for Antibiotic Resistance. She serves on the editorial board of six journals, is a member of the Product Development working group for Biodefense for the NIAID, is an Advisory Board Member of Optimer Pharmaceuticals, Inc. and has written numerous publications and books. She was awarded a post-doctoral fellowship to Fox Chase Cancer Center from the National Institutes of Health and received her Ph.D. in Microbiology from Thomas Jefferson University.

Mr. Moore is responsible for commercial development. He has spent over 15 years developing and managing pharmaceutical commercial programs, with the majority of those years spent with the Ortho-McNeil and Janssen Pharmaceutical divisions within Johnson & Johnson. Mr. Moore has held leadership roles in key sales and marketing functions, and was part of teams that developed and executed launch plans for several prescription pharmaceuticals for both primary and acute care settings. He developed payer value platforms for several therapeutic areas including antibiotics, pain and women’s health, in which he successfully implemented pricing and reimbursement strategies with hospitals and managed care organizations. Following Johnson & Johnson, he was chief business officer and vice president of Worldwide Commercial Operations of Tranzyme, Inc., where he was responsible for building the commercial organization as well as in- and out-licensing clinical-stage assets and was chief business officer of Ocera Therapeutics where he was responsible for developing the commercial plans for an Orphan-designated advanced liver disease product for both the community and acute care markets. Mr. Moore received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.